305 Therapeutic Potential of Opioids in Narcolepsy Type 1 (III). Respondents were then assisted to separate possible changes in their narcolepsy symptom severity after starting the opioid from possible changes due to the indication for which they started using the opioid. The type, dosage and duration of use was verified with the prescriber and/or pharmacist. Wilson 95% confidence intervals with continuity correction (CI) were provided for measures on opioid use in our population and the proportions of individuals that reported changes in narcolepsy type 1 symptom severity. All respondents provided informed consent prior to study start. In the Netherlands, research with negligible impact on subjects can be exempted from the Medical Scientific Research involving Human Subjects Act (WMO) and in this case a non-WMO declaration is necessary. The medical ethical committee of the VU Medical Center provided such a non-WMO-declaration for this study. The clinical experiments conformed to the principals outlined by the Declaration of Helsinki. 10
RkJQdWJsaXNoZXIy MjY0ODMw